Press Releases

Press Releases

All Releases
Mar 06, 2018
NEW YORK --(BUSINESS WIRE)--Mar. 6, 2018-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 9:20
Feb 27, 2018
(Conference Call and Webcast Today, February 27, 2018 , at 8:00 a.m. ET ) - Ophthotech Targets Novel Gene Therapy Technology for Orphan and Age-Related Retinal Diseases - - Complement C5 Inhibitor, Zimura ® , on Track with Four Ongoing Ophthalmic Clinical Programs - NEW YORK --(BUSINESS WIRE)--Feb.
Feb 27, 2018
– Ophthotech collaborates with University of Massachusetts Medical School on novel technology for next-generation gene delivery technology and novel gene therapies for ophthalmic diseases – – Collaboration is led by Guangping Gao and Hemant Khanna at UMass Medical School’s Horae Gene Therapy Center
Feb 21, 2018
NEW YORK --(BUSINESS WIRE)--Feb. 21, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its fourth quarter and full year 2017 financial and operating results on Tuesday, February 27, 2018 . Following the announcement, Ophthotech’s management team will host a live
Jan 16, 2018
- One of the Largest Interventional Clinical Trials for the Treatment of STGD1, an Inherited Orphan Retinal Disease – - Zimura Is Also Being Investigated in Ongoing Clinical Trials for the Treatment of Dry and Wet Age-related Macular Degeneration (AMD) and Idiopathic Polypoidal Choroidal
Jan 16, 2018
NEW YORK --(BUSINESS WIRE)--Jan. 16, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced today the election of Jane Pritchett Henderson , Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics , to its Board of Directors, effective immediately. Ms.
Jan 02, 2018
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)--Jan. 2, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 36th Annual J.P.
Nov 08, 2017
(Conference Call and Webcast Today, November 8, 2017 , at 8:00 a.m. ET ) - Complement C5 Inhibitor, Zimura ® , on Track to Have Four Ophthalmic Clinical Programs Ongoing by Year End - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced financial and operating results
Oct 30, 2017
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter 2017 financial and operating results on Wednesday, November 8, 2017 . Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00
Sep 19, 2017
- Company Initiates Phase 2a Clinical Trial in Patients with Wet Age-related Macular Degeneration - - Clinical Trials in Stargardt Disease and Idiopathic Polypoidal Choroidal Vasculopathy on Schedule to Initiate Before the End of the Year - - Company Modifies Plan for Study in Geographic Atrophy, a
Aug 14, 2017
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its Phase 3 clinical trial investigating the superiority of Fovista ® (pegpleranib) anti-PDGF therapy in
Jul 26, 2017
- Conference Call and Webcast Today, July 26, 2017 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the second quarter ended June 30, 2017 and provided a business update on its strategic plan.
Jul 26, 2017
(Conference Call Scheduled for today, July 26, 2017 at 8:00 a.m. ET ) - Stargardt Disease Clinical Trial Planned to Start Before the End of this Year - - Focus on Multiple Orphan Programs in Retinal Diseases and Continue Age-related Retinal Programs - - Business Development Efforts Ongoing - NEW
Jul 21, 2017
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its second quarter 2017 financial and operating results on Wednesday, July 26, 2017 . Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00
May 03, 2017
- Conference Call and Webcast Today, May 3, 2017 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the first quarter ended March 31, 2017 and provided a general business update.
Apr 26, 2017
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its first quarter 2017 financial and operating results on Wednesday, May 3, 2017 . Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00
Apr 24, 2017
- David R. Guyer , M.D. to Transition to Executive Chairman - - Glenn P. Sblendorio to Become Chief Executive Officer - - David F. Carroll Promoted to Chief Financial Officer, Effective Immediately - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that David R.
Feb 28, 2017
- Conference Call and Webcast Today, February 28 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the fourth quarter and full year ended December 31, 2016 and provided a general business update.
Feb 22, 2017
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its fourth quarter and full year 2016 financial and operating results on Tuesday, February 28, 2017 . Following the announcement, Ophthotech's management team will host a live conference call and
Feb 01, 2017
- Plan Designed to Evaluate Strategic Alternatives and Maximize Shareholder Value - - Announces Executive Changes: Glenn P. Sblendorio Assumes the Position of President and Keith Westby Takes on the Role of Chief Operating Officer - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT)